Bellerophon therapeutics receives ind clearance from china nmpa to conduct phase 3 clinical trial in china for inopulse® in fibrotic interstitial lung disease

China npma accepts the use of moderate to vigorous physical activity (mvpa) as the primary endpoint china npma accepts the use of moderate to vigorous physical activity (mvpa) as the primary endpoint

BLPH Ratings Summary

BLPH Quant Ranking